Argenx SE

Argenx SE

World Rank (Aug-2026)
483
Market Cap (Aug-2026)
52.834 Billion USD
World Rank (Jan-05-2024)
802
Market Cap (Jan-05-2024)
22.967 Billion USD
World Rank (Jul-30-2023)
621
Market Cap (Jul-30-2023)
30.537 Billion USD
World Rank (Jan-07-2022)
1,257
Market Cap (Jan-07-2022)
16.128 Billion USD
World Rank (Jan-01-2021)
1,255
Market Cap (Jan-01-2021)
14.022 Billion USD
Headquarters Country
Netherlands
Top Healthcare Companies in Europe
Top Technology Companies in Europe
Top Pharmaceutical Companies in Europe
Nasdaq / NYSE Code
ARGX
CEO
Tim Hauwermeiren
Employee Count
843
Employee Count as of Date
As on 2022
World Region
Europe
World Subregion
Western Europe
Annual Revenue in USD
4,153 Million USD
Annual Operating Income in USD
1,055 Million USD
Annual Net Income in USD
1,292 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
8,683 Million USD
Total Liabilities in USD
1,360 Million USD
Total Equity in USD
7,323 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Pharmaceutical
Biopharmaceutical
Biotechnology
Technology
Company Website
ARGENX SE
Yahoo
Yahoo @ Nasdaq
Company Profile

Biopharmaceutical company with headquarters is in Netherlands.

Annual Results Summary

ARGENX SE - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-2022410-719 (Loss)-709 (Loss)
Dec-2021497-348 (Loss)-408 (Loss)
Dec-202044-516 (Loss)-650 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 3,134 Million USD.

Total Liabilities as on Dec-2022 was 320 Million USD.

Total Equity as on Dec-2022 was 2,813 Million USD.

Founded Year
2008
IPO Year
2017
Stock Category
S&P EUROPE 350
EURONEXT 100
EURO STOXX 50
Stock Exchange
Nasdaq
Frankfurt
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share